FOLH1 and prostate carcinoma: They reported that [68Ga]-P137 demonstrated much lower uptake in the urinary tract than [68Ga]-PSMA-617 (SUVmax ratio of [68Ga]-P137/[68Ga]-PSMA-617:0.20 ± 0.07) and that both tracers showed moderate to high uptake in prostate cancer lesions without a significant uptake difference between the two tracers.